Combined cocaine hydrolase gene transfer and anti-cocaine vaccine synergistically block cocaine-induced locomotion

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Carroll, Marilyn E ^a   Zlebnik, Natalie E ^a   Anker, Justin J ^a   Kosten, Thomas R ^b   Orson, Frank M ^b   Shen, Xiaoyun ^b   Kinsey, Berma ^b   Parks, Robin J ^c   Gao, Yang ^d   Brimijoin, Stephen ^d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CHOLINESTERASE; COCAINE HYDROLASE; COCAINE VACCINE; HYDROLASE; ISO OMPA; KEYHOLE LIMPET HEMOCYANIN; NORCOCAINE; UNCLASSIFIED DRUG; VACCINE;

ABSTINENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DETOXIFICATION; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; HYPERACTIVITY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PROTECTION; RAT; SENSITIZATION; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANESTHETICS, LOCAL; ANIMALS; ANTIBODIES; BUTYRYLCHOLINESTERASE; COCAINE; COMBINED MODALITY THERAPY; GAIT DISORDERS, NEUROLOGIC; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MOTOR ACTIVITY; RATS; RATS, WISTAR; TIME FACTORS; TREATMENT OUTCOME; VACCINES;

EID: 84865063361     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043536     Document Type: Article

References (59)

1. Carrera MR, Ashley JA, Parsons LH, Wirsching P, Koob GF, et al. ((1995)) Suppression of psychoactive effects of cocaine by active immunization. Nature 378:: 727--730.
2. Kantak KM, Collins SL, Lipman EG, Bond J, Giovanoni K, et al. ((2000)) Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berl) 148:: 251--262.
3. Norman AB, Norman MK, Buesing WR, Tabet MR, Tsibulsky VL, et al. ((2009)) The effect of a chimeric human/murine anti-cocaine monoclonal antibody on cocaine self-administration in rats. J Pharmacol Exp Ther 328:: 873--881.
4. Norman AB, Tabet MR, Norman MK, Buesing WR, Pesce AJ, et al. ((2007)) A chimeric human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the brain in mice. J Pharmacol Exp Ther 320:: 145--153.
5. Kosten TR, Rosen M, Bond J, Settles M, Roberts JS, et al. ((2002)) Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 20:: 1196--1204.
6. Orson FM, Kinsey BM, Singh RA, Wu Y, Kosten TR, ((2009)) Vaccines for cocaine abuse. Hum Vaccin 5:: 194--199.
7. Wee S, Hicks MJ, De BP, Rosenberg JB, Moreno AY, et al. ((2012)) Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects. Neuropsychopharmacology 37:: 1083--1091.
8. Gorelick DA, ((1997)) Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Depend 48:: 159--165.
9. Koetzner L, Woods JH, ((2002)) Characterization of butyrylcholinesterase antagonism of cocaine-induced hyperactivity. Drug Metab Dispos 30:: 716--723.
10. Brimijoin S, Gao Y, Anker JJ, Gliddon LA, Lafleur D, et al. ((2008)) A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology 33:: 2715--2725.
11. Collins GT, Narasimhan D, Cunningham AR, Zaks ME, Nichols J, et al. ((2012)) Long-lasting effects of a PEGylated mutant cocaine esterase (CocE) on the reinforcing and discriminative stimulus effects of cocaine in rats. Neuropsychopharmacology 37:: 1092--1103.
12. Collins GT, Brim RL, Narasimhan D, Ko MC, Sunahara RK, et al. ((2009)) Cocaine esterase prevents cocaine-induced toxicity and the ongoing intravenous self-administration of cocaine in rats. J Pharmacol Exp Ther 331:: 445--455.
13. Cooper ZD, Narasimhan D, Sunahara RK, Mierzejewski P, Jutkiewicz EM, et al. ((2006)) Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase. Mol Pharmacol 70:: 1885--1891.
14. Kosten T, Owens SM, ((2005)) Immunotherapy for the treatment of drug abuse. Pharmacol Ther 108:: 76--85.
15. Orson FM, Kinsey BM, Singh RA, Wu Y, Kosten TR (2009) Vaccines for cocaine abuse. Hum Vaccin 5.
16. Martell BA, Orson FM, Poling J, Mitchell E, Rossen RD, et al. ((2009)) Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry 66:: 1116--1123.
17. Sun H, Pang YP, Lockridge O, Brimijoin S, ((2002)) Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol Pharmacol 62:: 220--224.
18. Pan Y, Gao D, Yang W, Cho H, Yang G, et al. ((2005)) Computational redesign of human butyrylcholinesterase for anticocaine medication. Proc Natl Acad Sci U S A 102:: 16656--16661.
19. Sun H, El Yazal J, Lockridge O, Schopfer LM, Brimijoin S, et al. ((2001)) Predicted Michaelis-Menten complexes of cocaine-butyrylcholinesterase. Engineering effective butyrylcholinesterase mutants for cocaine detoxication. J Biol Chem 276:: 9330--9336.
20. Pan Y, Gao D, Yang W, Cho H, Zhan CG, ((2007)) Free energy perturbation (FEP) simulation on the transition states of cocaine hydrolysis catalyzed by human butyrylcholinesterase and its mutants. J Am Chem Soc 129:: 13537--13543.
21. Xue L, Ko MC, Tong M, Yang W, Hou S, et al. ((2011)) Design, preparation, and characterization of high-activity mutants of human butyrylcholinesterase specific for detoxification of cocaine. Mol Pharmacol 79:: 290--297.
22. Gao Y, Brimijoin S, ((2009)) Lasting reduction of cocaine action in neostriatum-a hydrolase gene therapy approach. J Pharmacol Exp Ther 330:: 449--457.
23. Anker JJ, Brimijoin S, Gao Y, Geng L, Zlebnik NE, et al. (2011) Cocaine Hydrolase Encoded in Viral Vector Blocks the Reinstatement of Cocaine Seeking in Rats for 6 Months. Biol Psychiatry.
24. Gao Y, Orson FM, Kinsey B, Kosten T, Brimijoin S, ((2010)) The concept of pharmacologic cocaine interception as a treatment for drug abuse. Chem Biol Interact 187:: 421--424.
25. Zhou SJ, Xue LF, Wang XY, Jiang WG, Xue YX, et al. (2011) NMDA receptor glycine modulatory site in the ventral tegmental area regulates the acquisition, retrieval, and reconsolidation of cocaine reward memory. Psychopharmacology (Berl).
26. Robinson TE, Berridge KC, ((2003)) Addiction. Annu Rev Psychol 54:: 25--53.
27. Vezina P, ((2004)) Sensitization of midbrain dopamine neuron reactivity and the self-administration of psychomotor stimulant drugs. Neurosci Biobehav Rev 27:: 827--839.
28. Ferrario CR, Li X, Wang X, Reimers JM, Uejima JL, et al. ((2010)) The role of glutamate receptor redistribution in locomotor sensitization to cocaine. Neuropsychopharmacology 35:: 818--833.
29. Gao Y, Atanasova E, Sui N, Pancook JD, Watkins JD, et al. ((2005)) Gene transfer of cocaine hydrolase suppresses cardiovascular responses to cocaine in rats. Mol Pharmacol 67:: 204--211.
30. Kantak KM, ((2003)) Anti-cocaine vaccines: antibody protection against relapse. Expert Opin Pharmacother 4:: 213--218.
31. Kantak KM, Collins SL, Bond J, Fox BS, ((2001)) Time course of changes in cocaine self-administration behavior in rats during immunization with the cocaine vaccine IPC-1010. Psychopharmacology (Berl) 153:: 334--340.
32. Chou TC, Talalay P, ((1984)) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:: 27--55.
33. Riday TT, Kosofsky BE, Malanga CJ, ((2012)) The rewarding and locomotor-sensitizing effects of repeated cocaine administration are distinct and separable in mice. Neuropharmacology 62:: 1858--1866.
34. LeSage MG, Keyler DE, Pentel PR, ((2006)) Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. Aaps J 8:: E65--75.
35. Kinsey BM, Kosten TR, Orson FM, ((2010)) Active immunotherapy for the Treatment of Cocaine Dependence. Drugs Future 35:: 301--306.
36. Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR, ((2005)) Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 58:: 158--164.
37. Muruve DA, ((2004)) The innate immune response to adenovirus vectors. Hum Gene Ther 15:: 1157--1166.
38. Muruve DA, Cotter MJ, Zaiss AK, White LR, Liu Q, et al. ((2004)) Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol 78:: 5966--5972.
39. Brunetti-Pierri N, Palmer DJ, Beaudet AL, Carey KD, Finegold M, et al. ((2004)) Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 15:: 35--46.
40. Mane VP, Toietta G, McCormack WM, Conde I, Clarke C, et al. ((2006)) Modulation of TNFalpha, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors. Gene Ther 13:: 1272--1280.
41. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, et al. ((2006)) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12:: 342--347.
42. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, et al. ((2003)) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80:: 148--158.
43. Saxena A, Sun W, Fedorko JM, Koplovitz I, Doctor BP, ((2011)) Prophylaxis with human serum butyrylcholinesterase protects guinea pigs exposed to multiple lethal doses of soman or VX. Biochem Pharmacol 81:: 164--169.
44. Saxena A, Sun W, Luo C, Doctor BP, ((2005)) Human serum butyrylcholinesterase: in vitro and in vivo stability, pharmacokinetics, and safety in mice. Chem Biol Interact 157-158:: 199--203.
45. Weber A, Butterweck H, Mais-Paul U, Teschner W, Lei L, et al. ((2011)) Biochemical, molecular and preclinical characterization of a double-virus-reduced human butyrylcholinesterase preparation designed for clinical use. Vox Sang 100:: 285--297.
46. Pan Y, Gao D, Zhan CG, ((2008)) Modeling the catalysis of anti-cocaine catalytic antibody: competing reaction pathways and free energy barriers. J Am Chem Soc 130:: 5140--5149.
47. Yang W, Xue L, Fang L, Chen X, Zhan CG, ((2010)) Characterization of a high-activity mutant of human butyrylcholinesterase against (-)-cocaine. Chem Biol Interact 187:: 148--152.
48. Hicks MJ, De BP, Rosenberg JB, Davidson JT, Moreno AY, et al. (2011) Cocaine Analog Coupled to Disrupted Adenovirus: A Vaccine Strategy to Evoke High-titer Immunity Against Addictive Drugs. Mol Ther.
49. Orson FM, Kinsey BM, Singh RA, Wu Y, Gardner T, et al. ((2007)) The future of vaccines in the management of addictive disorders. Curr Psychiatry Rep 9:: 381--387.
50. Orson FM, Kinsey BM, Singh RA, Wu Y, Gardner T, et al. ((2008)) Substance abuse vaccines. Ann N Y Acad Sci 1141:: 257--269.
51. National Research Council (2011) Guide for the care and use of laboratory animals. In: Council NR, editor. Eighth ed. Washington DC: National Academies Press.
52. Li Y, Acerbo MJ, Robinson TE, ((2004)) The induction of behavioural sensitization is associated with cocaine-induced structural plasticity in the core (but not shell) of the nucleus accumbens. Eur J Neurosci 20:: 1647--1654.
53. Gao Y, LaFleur D, Shah R, Zhao Q, Singh M, et al. ((2008)) An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties. Chem Biol Interact 175:: 83--87.
54. Brimijoin S, Shen M, Sun H, ((2002)) Radiometric solvent-partitioning assay for screening cocaine hydrolases and measuring cocaine levels in milligram tissue samples. Analytical Biochemistry 309:: 200--205.
55. Gao Y, Brimijoin S, ((2004)) An engineered cocaine hydrolase blunts and reverses cardiovascular responses to cocaine in rats. J Pharmacol Expt Ther 310:: 1046--1052.
56. Johnson CD, Russell RL, ((1975)) A rapid simple radiometric assay for cholinesterase, suitable for multiple determinations. Anal Biochem 64:: 229--238.
57. Kim IH, Jozkowicz A, Piedra PA, Oka K, Chan L, ((2001)) Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A 98:: 13282--13287.
58. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, et al. ((1996)) A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci 93:: 13565--13570.
59. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, et al. ((1996)) A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 93:: 13565--13570.